Avalon Pharmaceuticals to Participate in the Susquehanna Financial 2007 SIGnificant Investment Options in Healthcare Conference
February 27 2007 - 3:45PM
PR Newswire (US)
GERMANTOWN, Md., Feb. 27 /PRNewswire-FirstCall/ -- Avalon
Pharmaceuticals, Inc. (Nasdaq and NYSE ArcaEx: AVRX), today
announced that Gary Lessing, Executive Vice President and Chief
Financial Officer, is scheduled to provide an update on the company
at the 2007 SIGnificant Investment Options in Healthcare Conference
sponsored by Susquehanna Financial Group, LLLP. The meeting will be
held at the Omni Berkshire Place in New York City on March 1, 2007.
Mr. Lessing is scheduled to present at 8:30 a.m. EST, in the
Metropolitan Room. A live audio webcast of this presentation can be
accessed on Avalon Pharmaceuticals' website,
http://www.avalonrx.com/ and a replay of the presentation will be
available for 90 days following the conference. Mr. Lessing is also
scheduled to participate in a panel discussion entitled, "New World
Order: Convergence of Healthcare Investors." That discussion will
be held from 4:00 p.m. - 5:00 p.m. EST, in the Julliard Ballroom.
About Avalon Pharmaceuticals Avalon Pharmaceuticals is a
biopharmaceutical company using its proprietary technology,
AvalonRx(R), to discover and develop cancer therapeutics. Avalon
has a lead product in Phase I clinical development (AVN944 - IMPDH
inhibitor), as well as preclinical programs to discovery inhibitors
for the beta-catenin and aurora pathways now in late stage lead
candidate optimization. Avalon also has discovery programs on
modulators of survivin function and a drug discovery program
targeting the MYC oncoprotein, one of the most important and
previously intractable cancer targets. The company has value
generating partnerships with MedImmune, Medarex, and Novartis.
Avalon Pharmaceuticals was established in 1999 and is headquartered
in Germantown, Md. About AvalonRx(R) AvalonRx(R) is a
comprehensive, innovative and proprietary suite of technologies
based upon large-scale gene expression analysis. This platform
facilitates drug discovery by expanding the range of therapeutic
targets for drug intervention, including targets and target
pathways frequently considered intractable using conventional HTS
approaches, allows more informed decisions about which compounds to
advance towards clinical trials, and facilitates drug development
through identification of biomarkers of efficacy that can stratify
patients or provide early indicators of response. Forward-Looking
Statements This press release contains "forward-looking statements"
within the meaning of the United States Private Securities Reform
Act of 1995. These statements are based on management's current
expectations and are subject to risks, uncertainty and changes in
circumstances, which may cause actual results, performance or
achievements to differ materially from anticipated results,
performance or achievements. All statements contained herein that
are not clearly historical in nature are forward looking. Economic,
business, competitive and/or regulatory factors affecting Avalon's
business are examples of factors, among others, that could cause
actual results to differ materially from those described in the
forward-looking statements. All forward-looking statements are also
expressly qualified in their entirety by the cautionary statements
included in Avalon's Securities and Exchange Commission filings,
including its quarterly reports on Form 10-Q and its annual report
on Form 10-K. Avalon is under no obligation to (and expressly
disclaims any such obligation to) update or alter its
forward-looking statements whether as a result of new information,
future events or otherwise. Contacts: Avalon Pharmaceuticals, Inc.
Noonan Russo Gary Lessing Wendy Lau (Media) Executive Vice
President & CFO Tel: (212) 845-4272 Tel: (301) 556-9900 Fax:
(301) 556-9910 The Trout Group LLC Email: Chad Rubin (Investors)
Tel: (212) 477-9007 ext. 47 DATASOURCE: Avalon Pharmaceuticals,
Inc. CONTACT: Gary Lessing, Executive Vice President & CFO of
Avalon Pharmaceuticals, Inc., Tel: +1-301-556-9900, or Fax:
+1-301-556-9910, or ; or Media, Wendy Lau, of Noonan Russo for
Avalon Pharmaceuticals, Inc., +1-212-845-4272; or Investors, Chad
Rubin of The Trout Group LLC for Avalon Pharmaceuticals, Inc.,
+1-212-477-9007 ext. 47 Web site: http://www.avalonrx.com/
Copyright